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Angiogenesis is the formation of new blood vessels from preexisting vasculature. Uncontrolled 
angiogenesis is associated with progression of several ocular pathologies, such as diabetic retinopathy 
and macular degeneration. Thus, the inhibition of this process consists in an interesting therapeutic 
target. Corosolic acid (CA) is a natural derivative of ursolic acid, found in many medicinal herbs 
and exhibits numerous biological properties, including the antiangiogenic activity. The present 
study reports the production of CA-loaded poly d,l-lactidecoglycolide acid (PLGA) devices by melt 
technique. HPLC-UV method was developed and validated to evaluate the uniformity and the release 
profile of the developed systems. The devices were also characterized by Fourier transform infrared 
spectroscopy, thermal analysis, and scanning electron morphology. It was studied the antiangiogenic 
activity of the CA-polymer system, using an in vivo model, the chorioallantoic membrane assay 
(CAM). CA was dispersed uniformly in the polymer matrix and no chemical interaction between 
the components of the formulation was verified. The implants presented a sustained release of the 
drug, which was confirmed by the morphological study and demonstrated an antiangiogenic activity. 
Therefore, the developed delivery system is a promising therapeutic tool for the treatment of ocular 
diseases associated with neovascularization or others related to the angiogenic process.
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INTRODUCTION
Angiogenesis or neovascularization is a natural 
process responsible for the formation of new blood 
vessels from preexisting vasculature (Elshabrawy et al., 
2015). The neovascularization is controlled by several 
molecules that stimulate (pro-angiogenic) and inhibit 
(antiangiogenic) the formation of new blood vessels 
(Gacche, Meshram, 2014). In normal physiological 
conditions, there is a dynamic balance between pro-
angiogenic and antiangiogenic factors. However, in 
pathological circumstances, the balance between 
these factors is lost by some chemical, mechanical, 
degenerative or infectious stimulus, resulting in 
hyperstimulation of pro-angiogenic factors which leads 
to an uncontrolled cell multiplication and formation 
of functionally and structurally disordered neovessels 
(Behl, Kotwani, 2015).
Among the factors involved in angiogenesis, 
vascular endothelial growth factor (VEGF) is one of 
the most important pro-angiogenic factors, due to 
its vascular endothelium specificity and its ability to 
induce vasodilation via NO endothelial production. 
Under hypoxic conditions, VEGF is excessively 
produced, resulting in dysregulated angiogenesis 
that plays an important role in the progression of 
several pathologies, such as proliferative diseases of 
retina, chronic inflammation, rheumatoid arthritis, 
psoriasis, endometriosis, tumor growth and metastasis 
(Kanjoormana, Kuttan 2010; Katrancioglu et al., 
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2012). Therefore, the inhibition of this process may 
be an interesting therapeutic target, especially for the 
treatment of ocular neovascularization diseases. New 
drugs are still be sought to antiangiogenic therapy 
and, based on this, plant-derived compounds comprise 
potential pharmacological agents (Balakrishnan, Al 
Assaf, 2016). 
Pentacyclic triterpenes are secondary metabolites 
widely distributed in the plant kingdom, which 
are commonly object of pharmacological and 
phytochemical research (Nazaruk, Borzym-Kluczyk, 
2014). According to their skeleton, they are divided 
into some groups, of which the ursanes and oleanes 
are the most common structures (Alvarado et al. 
2015b). Representatives of those, such as ursolic 
acid, maslinic acid and oleanolic acid were previously 
reported to have antiangiogenic properties (Hussain 
et al., 2012; Kanjoormana, Kuttan, 2010; Kashyap et 
al., 2018; Thakor et al., 2017; Zhu et al., 2013). In this 







; molar mass 472.71 g.mol-1). CA 
(2α-hydroxyursolic acid) is a natural derivative of 
ursolic acid, that can be found in many medicinal herbs 
such as: Lagerstroemia speciosa (banaba) (Yang et al., 
2016), Ugni molinae (murtilla) (Arancibia-Radich et 
al., 2016), Eriobotrya japonica (loquat) (Tan, Sonam, 
Shimizu, 2017) and Jacaranda oxyphylla Cham. 
(“caroba-de-São-Paulo”) (Pereira et al., 2016). 
It has been reported that CA exhibits numerous 
biological properties, including antidiabetic (Nazaruk, 
Borzym-Kluczyk, 2014; Yang et al., 2016), antioxidative 
(Li et al., 2016), anti-tumoral (Cheng et al., 2017), 
antiseptic and anti-aging (Tan et al., 2017) activities. 
Recently, it was demonstrated that CA also presents 
antiangiogenic activity (Ku et al., 2015; Yoo et al., 2015). 
Ku and collaborators have demonstrated that CA is able 
to block the ATP binding site, resulting in inhibition of 
VEGFR2 kinase activity, which is a major receptor that 
participates in the angiogenesis process (Ku et al., 2015).
Currently, there is a compelling need for the 
development of biodegradable ophthalmic polymeric 
system for controlled and local release. This kind 
of technology offers some advantages, such as the 
availability of the drug directly at the site of action, 
reduction of adverse systemic effects and administration 
frequency, meaning improvement in patient compliance, 
safety and efficacy (Patel et al., 2013; Ma et al., 2017). 
PLGA (poly d,l-lactidecoglycolide acid), a biodegradable 
and biocompatible polymer, approved by the Food and 
Drug Administration (FDA) and the European Medicine 
Agency (EMA), is the main used carrier for sustained 
drug delivery.
Implantable polymeric drug delivery systems 
have been proposed for ocular applications and some 
medicines have been approved by the FDA, for example, 
Ozurdex® and Iluvien®. In addition, there is no report 
of non-steroidal drugs approved by the FDA for the 
treatment of pathologies associated with angiogenesis, 
what justifies this study. Furthermore, it has been 
reported the success of the association between PLGA 
and triterpenes in terms of incorporation and efficacy 
(Alvarado et al., 2015a; Soares et al., 2017). However, 
at present, no study has designed a PLGA device 
to vehiculize CA in a sustained release system for 
angiogenic pathologies. Based on this, this work aimed 
to develop and evaluate the antiangiogenic activity of 
CA-loaded PLGA implant, envisioning its application 
in the treatment of ocular diseases associated with 
neovascularization. 
MATERIAL AND METHODS
Chemical and reagents 
Poly (D, L-lactide-coglycolide) in ratio of 50:50 
[PLGA (50:50)] was purchased from Boehringer 
Ingelheim (Germany). Corosolic acid (MW 472.71, 
obtained from Jacaranda oxyohylla) was offered 
by the Center of Studies and Research in Medicinal 
Plants of Chemistry Department of UFMG (Belo 
Horizonte, Brazil) and the corosolic acid chemical 
reference substance was purchased from Sigma 
Aldrich (USA) (MW 472.71, purity ≥ 98%). Ultrapure 
water was produced by a Milli-Q® purification system 
(Millipore, USA). Methanol was purchased from 
Merck (Brazil). The other solvents and reagents used 
were of analytical grade.
PLGA-CA implant preparation
Implants were prepared by the hot molding 
technique according to the procedure described by 
Fialho and Silva-Cunha (2007). The PLGA 50:50 
implants were loaded with 15% (w/w) of CA (Yasukawa 
et al., 2005). Firstly, CA and PLGA were dissolved in 90 
µL of DMSO and an appropriate quantity of acetonitrile 
as the organic solvent. This suspension was lyophilized. 
The obtained powder was molded into rods using a 
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Teflon® sheet heated at the temperature of 100-120 °C. 
The mean weight of the implants was 1.21 ± 0.06 mg.
Development of chromatographic method
HPLC-UV analyses were carried out on an Agilent® 
1260 Infinity System (USA) using the analytical column 
LiChrosorb ® RP-18, 250 x 4.6 mm; 5 µm (Merck, 
Brazil). The compound was detected at a wavelength of 
210 nm with a flow rate of 0.8 mL min-1. Organic solvents 
such as acetonitrile, methanol, and aqueous phases as 
water, phosphate acid 0.1% and formic acid 0.1% were 
tested at different rates to select the best mobile phase. 
Finally, the mobile phase methanol: water: formic acid 
(88:12:0.1 v/v/v, pH = 6.8) was chosen because offered 
the best peak shape. The injection volume was 20 µL. All 
determinations were performed at 40 °C under isocratic 
elution. The retention time observed for the samples was 
about 11 minutes.
Preparation of solutions 
Standard solution
5 mg of CA reference standard were accurately 
weighed and transferred to a 5 mL volumetric flask and 
dissolved in methanol to obtain a final concentration of 1 
mg mL-1. All the standard solutions were filtered through 
0.45 µm filter (Sartorius, Germany). The concentration 
of CA in each solution prepared was defined in the 
description of the validation parameter.
Placebo solution
The implant of PLGA (without drug) was transferred 
to a 1 mL volumetric flask. One drop of acetonitrile was 
added to ensure complete solubilization, and the volume 
was adjusted with methanol. The placebo solution was 
filtered through 0.45 µm filter (Sartorius, Germany).
Analytical method validation 
Validation of the developed method was carried 
out as preconized by the International Conference on 
Harmonization Guidelines for validation of analytical 
procedures (International Conference on Harmonisation, 
2005). It included the evaluation of selectivity, calibration 
curve, precision, accuracy, robustness, detection and 
quantitation limits (LOD and LOQ).
Selectivity was confirmed by comparing the 
chromatographic peaks of CA reference-standard, blank 
samples of methanol, mobile phase and PLGA solution. 
To achieve selectivity of the method, no peak with the 
same retention time of CA is allowed.
Linearity was evaluated by constructing the 
calibration curves at six concentration levels in the 
range of 50 – 300 µg mL-1 for CA standard solution in 
three independent experiments. The calibration curves 
constructed were assessed using residue analysis 
(homoscedasticity, normality and independence 
of residues) and the linear regression was done by 
the weighted least squares method. The correlation 
coefficient was calculated. The limit of detection (LOD) 
and limit of quantification (LOQ) were calculated from 
the calibration curve, considering the residual standard 
deviation of regression line.
Precision was determined based on repeatability 
(intra-assay) and intermediate precision (inter-assay). 
Repeatability was performed through the assay of 
three solutions (100, 200 e 300 µg mL-1) on the same 
day. Intermediate precision was verified by evaluating 
the results in two consecutive days. The solutions were 
prepared in triplicate. 
Recovery test was carried out to determine the 
accuracy. For this, three solutions (100, 200 e 300 µg ml-
1) were prepared in triplicate by the incorporation of CA 
standard in placebo solution.
Robustness was studied by determining the effects 
of small variations of mobile phase composition, the 
flow rate and temperature. 
Determination of CA content in 
the polymeric-systems
Immediately after the production, an amount of 
ten biodegradable CA-loaded PLGA implants were 
weighted and transferred to a 1 ml volumetric flask. 
One drop of acetonitrile was added to ensure complete 
solubilization, and the volume was adjusted with 
methanol. All the sample solutions were filtered through 
0.45 µm filter (Sartorius, Germany). The amount 
of CA was determined by high performance liquid 
chromatography method described above. The CA 
concentration was calculated by the area under the curve 
and the results were expressed as the percentage content 
of the pre-indicated value (15.0%).
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Physicochemical characterization
Fourier transform infrared spectroscopy (FTIR)
The FTIR spectra of the samples constituted 
by CA; PLGA and CA loaded PLGA implants were 
recorded on the Frontier Single Ranger (MIR) 
Spectrometer (Perkin-Elmer) and measurements were 
carried out using the Attenuated Total Reflectance 
(ATR) technique, in the range of 4000 -550 cm-1, of 16 
scans and a resolution of 4 cm-1. 
Thermal analysis 
Thermal behavior of the samples was analyzed 
by thermogravimetry (TG) and differential scanning 
calorimetry (DSC) using a DSC-50 (Shimadzu). The 
samples constituted by CA; PLGA; a physical mixture of 
CA and PLGA and CA loaded PLGA implants were heated 
in semi-hermetic aluminum pans from 25 °C to 300 °C 
(10 °C min-1) under nitrogen atmosphere (50 ml min-1).
Morphological characterization 
The structure of CA-loaded PLGA implants was 
examined morphologically using a Scanning Electron 
Microscope (JEOL JSM6360LV) operating at 15 kV. All 
micrographs were obtained from the fracture surfaces 
coated with gold. The surfaces of the implants were 
observed at 100 – 5000 magnification.
In vitro CA release study
In vitro release of CA from CA-loaded PLGA 
implants was carried out in triplicate in the release 
medium (PBS buffer, pH 7.4). Each implant, previously 
weighted, was immersed in 4 ml of PBS in a closed flask. 
These flasks were kept inside an incubator (TECNAL, 
model TE-424) set at 37 °C and 30 rpm. Along 54 days, 
at predetermined intervals (weeks 1, 2, 4, 6 and 8) three 
implants were taken out.
In order to evaluate water absorption by the implants 
and weight loss, the implants were weighed immediately 
and 72 hours after the collection. The weight variation 
was calculated by the following equation and expressed 
as a percentage.
Δ weight (%) = 100 x (wo-wf)/wo
Where wo is the initial weight and wf is the weight 
after the release study.
Then, the implants were quantified by HPLC-
UV method previously described and expressed as the 
weekly and cumulative percentage of CA released in the 
medium, calculated by:
CA released (%) = 100 x (Qo-Qf)/wo
Where Qo is the initial amount of CA and Qf is the 
amount of CA in implant after the release study.
In vivo antiangiogenic study
In order to investigate the antiangiogenic activity, 
CA-loaded PLGA implants in 15% (w/w) were applied 
in the chorioallantoic membrane (CAM) assay. For this 
purpose, 50 freshly fertilized eggs (Gallus domesticus) 
were previously incubated for 72 hours at 37 °C and 
relative air humidity of 60%. Then, a circular hole of 
approximately 1 cm of diameter was made in the eggshell 
air chamber. The inner shell membrane was removed to 
expose the CAM (day 3). The windows in the eggshell 
were covered with an adhesive tape and thereafter, the 
eggs were incubated for more 48 hours. Subsequently, 
on the 5th day, the tapes were removed and the samples 
were applied over the CAM in a predetermined site. The 
tapes were placed again and the eggs were incubated for 
more 48 hours. On the 7th day of embryo development, 
CAMs were fixed with a formaldehyde solution 
10% during 10 minutes. Then, the membranes were 
extracted and analyzed with a stereomicroscope (Motic 
® SMZ168) coupled to a digital camera (Motic cam). 
For CAM vasculature evaluation, the obtained images 
were converted to the grayscale using ImageJ software 
(version 1.50i National Institutes of Health, USA) and 
the negative control group was set to 100% for blood 
vessels quantification.
The samples applied to the CAMs were PBS buffer 
pH 7.4 (50 µL) as the negative control; bevacizumab 
solution at 250 µg ml-1 (50 µL) as the positive control; 
PLGA blank implants; CA-loaded PLGA implants and 
CA suspension at 250 µg ml-1 (50 µL).
The concentration of CA suspension was based on 
CA daily release from the implants obtained during the 
in vitro study. Therefore, this concentration was calculated 
considering a linear release of CA during 60 hours.
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Statistical analysis
Statistical evaluation of the data was performed 
using one-way analysis of variance (ANOVA) followed 
by post-test of Tukey to compare the significance 
between the different groups, using the software 
GraphPad Prism®5. A p-value < 0.05 was considered 
statistically significant.
RESULTS AND DISCUSSION
Analytical method validation 
HPLC-UV method was developed and validated for 
quantitative determination of CA content incorporated 
into polymeric systems and released from these devices. 
Representative chromatographic profile of CA in 
the presence of possible interferes is shown in Figure 
1. Any interfering peaks were observed at the retention 
time of CA (11.4 minutes) and thus, the method was 
considered specific.
A great linearity was obtained over a concentration 
range of 50 – 300 µg mL-1. The calibration curve could 
be defined by the following equation: y= 1465752.5268x 
– 3892851.8889, where y attends for the area under the 
curve and x the concentration (µg.mL-1). The correlation 
coefficient of the obtained curve was 0.9993, indicating 
a highly significant correlation between concentration 
and peak area. Through the weighted least square 
method, the linear model proved to be adequate since 
the residues followed a normal distribution pattern, were 
independent and homoscedastic. In addition, the lack of 
fit was not significant. 
The LOD and LOQ were estimated to check the 
sensitivity of the method. The signal-to-noise ratio for 
LOD was considered as 3:1 and 10:1 for LOQ. The 
LOD and LOQ were found to be 0.91 and 2.75 µg mL-1, 
respectively.
Repeatability and intermediate precision were 
expressed as the relative standard deviation (RSD). 
The results obtained are presented in Table I, and 
the values in both cases were satisfactory, presenting 
values less than 1.7.
Accuracy was calculated as a percentage of the 
recovery test and the results are shown in Table I. The 
recovery values were within the acceptable limits (98 
– 102%) and the RSD was lower than 2%, proving the 
accuracy of the developed method.
Moreover, the developed method proved to be 
robust for temperature changes. The flow rate and 
mobile phase composition should be carefully controlled 
since modifications in these parameters could affect the 
retention time and the symmetry of CA peak.
FIGURE 1 - Overlapped chromatograms obtained during selectivity study, under experimental conditions.
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TABLE I - Validation parameters for CA quantification
Precision intra-assay












Determination of CA content in 
the polymeric-systems
CA content in the developed devices was quantified 
by the chromatographic method described. The mean of 
the drug incorporated into polymeric systems was 77.06 
± 2.32% (n=10) of the pre-indicated value (15% w/w) and 
CA was dispersed uniformly in the polymeric matrix.
Physicochemical characterization
Fourier transform infrared spectroscopy (FTIR)
FTIR technique was applied to investigate the 
occurrence of possible chemical interactions between 
CA and PLGA chains and subsequent modifications 
in the original molecular structure, which could lead 
to changes or loss of biological activity. The FTIR 
spectrum of CA (Figure 2A) showed absorption bands 
at 3383 cm-1, corresponding to the stretching of O-H 
linkage of alcohol and carboxylic acid, at 2926 and 2864 
cm-1, referring to stretching of C-H (Li et al., 2014). 
The absorption bands at 1457 and 1377 cm-1 refer to the 
angular deformation of C-H linkage of aliphatic groups. 
There is also two overlapped bands at 1748 and 1687 
cm-1 related, respectively, to C=O stretching from acid 
monomers and aggregated species which means that 
a great part of CA is in form of dimers or aggregates. 
Similar results were observed by Lorincz et al. (2015).
FTIR spectrum of blank PLGA 50:50 (Figure 2B) 
presented a characteristic band at 1759 cm-1, assigned to 
stretching of ester carbonyl groups (C=O). Stretching 
and angular deformations of C-H were observed, 
respectively, at 2998 and 2951 cm-1 and from 1450 to 
1375 cm-1. Similar types of bands were also observed in 
previous works (Vey et al., 2011; Keles et al., 2014).
Typical absorption bands of the functional groups 
of CA and PLGA 50:50 were demonstrated in the 
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FTIR spectra of the physical mixture (CA+ PLGA) 
and of CA-loaded PLGA implants (Figure 2C) and no 
new bands were observed. Thus, the structure of both 
compounds has remained stable, indicating that no 
effective chemical bond has been occurred between then 
(Soares et al., 2017). Moreover, it was evidenced the 
quality of the manufacturing process, since the presence 
of absorption bands referred to the solvents employed 
during the preparation of CA-loaded PLGA implants 
was not observed. 
FIGURE 2 - FTIR spectra of CA (A), PLGA (B); physical 
mixture (C); CA-loaded PLGA implant (D).
Thermal analysis
Thermal analysis was employed to evaluate 
the possibility of any physical-chemical interaction 
between CA and PLGA 50:50 within the polymeric 
matrix. TG thermogram of CA, PLGA and CA-
loaded PLGA implants (Figure 3) showed a single 
well-defined event corresponding to the thermal 
degradation at temperatures up to 250 °C (Solano 
et al., 2013). Only the physical mixture showed two 
events of degradation, the first referring to PLGA and 
the second related to CA. 
The DSC curve of CA (Figure 4A) showed an 
endothermic event at 255 °C (T onset at 251 °C), 
attributed to the melting point of this substance (El-
moghazy et al. 2016). PLGA 50:50 (Figure 4B) 
presented an endothermic reaction at 54 °C in this 
DSC curve, which is correlated to the glass transition 
(Jahangiri et al., 2014; Sun et al., 2015). Due to the 
amorphous phase of the polymer, events indicating the 
melting point of PLGA 50:50 was not demonstrated 
(Soares et al., 2017). DSC curve of the physical 
mixture presented both endothermic events (at 54° and 
255 °C). Finally, the DSC curve of CA-loaded PLGA 
implant (Figure 4C) showed an endothermic process at 
55 °C, referring to the PLGA glass transition. However, 
the peak of CA at 255 °C disappeared or diminished 
considerably, indicating the complete entrapment 
of CA by the polymer chains (Anwer et al., 2016) or 
by the drug transition to the amorphous state during 
the liofilization process (Eloy, Marchetti, 2014). No 
other significant peak was observed in DSC curves, 
supporting that no significant chemical changes or 
interactions occurred between CA and PLGA, as 
observed in the FTIR analysis.
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FIGURE 3 - TG curves of CA, PLGA, physical mixture, CA-loaded PLGA implant.
FIGURE 4 - DSC curves of (A) CA; (B) PLGA; (C) physical mixture; (D) CA-loaded PLGA implant.
Morphological characterization 
Morphological study was conducted to investigate 
the microstructure of CA-loaded implants (Figure 5) 
in the initial time and after 15 and 30 days of the drug 
release study. Micrographs revealed a homogeneous 
and smooth surface with no evidence of pores or 
channels before the beginning of the drug release test. 
However, the surfaces of the implants with 15 and 30 
days of release study, was found to be heterogeneous 
and with a few pores and channels, indicating the 
process of matrix erosion. In this context, the CA 
dispersed in the polymer matrix can be released 
through the pores by diffusion, degradation of the 
polymer or a combination of the two mechanisms 
(Boimvaser et al., 2016; Cossé et al., 2017).
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FIGURE 5 - SEM images of the external surface of CA-loaded PLGA implants: (A) before (B) 15 days and (C) 30 days of release 
study. Magnification of 20x. 
four weeks, no relevant weight loss of the implant 
was shown, which is attributed to the initial phase 
of PLGA degradation process. During this period, a 
high water absorption occurred, which promoted ester 
bonds hydrolysis of the polymer structure (Boimvaser 
et al., 2016; Cossé et al., 2017), culminating with the 
appearance of pores in the matrix and, subsequently, 
the beginning of implant weight loss process. Although 
there were new channels in the polymer matrix, the 
CA release to the medium occurred slowly due to the 
hydrophobic structure of CA, which may contribute to 
its higher affinity for the matrix and a reduction of the 
diffusion rate. 
In vitro CA release study
CA release profile from PLGA implants in PBS 
buffer pH 7.4 is presented in Figure 6A and the erosion 
profile is shown in Figures 6B-C. A prolonged release 
of CA over 54 days was observed, characterized by 
a biphasic profile. In the first stage, there was a low 
burst release of CA; around 25% of CA content was 
released in the week 1, which could be related to 
the presence of CA associated to the surface of the 
polymer matrix. In the second stage, between weeks 
2 and 8, around 60% of CA was released, with an 
approximately weekly rate of 10%. During the first 
FIGURE 6 - In vitro release profile of CA from the polymeric device: (A) cumulative release of CA; (B) water absorption (C) 
weight loss.
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In vivo antiangiogenic study
Antiangiogenic activity of PLGA-CA devices was 
evaluated by CAM assay, which is a non-invasive, easy 
and a low-cost model (Kue et al., 2015). In this study, 
the antiangiogenic effect of CA was compared with that 
of bevacizumab, which is a well-known antiangiogenic 
drug used clinically. This drug is actually approved 
for the treatment of a few types of cancer, such as 
colorectal, lung and kidney. Furthermore, it is off-label 
used in the treatment of angiogenic pathologies of retina 
(Katrancioglu et al., 2012).
According to Figure 7, no statistical difference 
was observed between the groups treated with PBS 
and PLGA. Thus, the topical application of PLGA 
did not induce any decrease in vascularity. However, 
the treatment with CA-loaded PLGA implants was 
significantly different from the treatment with PLGA 
or PBS. CA-loaded PLGA implants lead to a reduction 
of approximately 17.5% in the vessels. A significant 
antiangiogenic effect was observed for membranes 
treated with CA suspension at 250 µg mL1, which induced 
a reduction of 48.4% in the vessels. Bevacizumab at 250 
µg mL-1 was used as a positive control and provoked an 
antiangiogenic effect of 50%. No significant difference 
was found between bevacizumab at 250 µg mL-1 and CA 
suspension at 250 µg mL-1.
According to the in vitro study, considering that 
around 25% of CA content was released on the first 
week, we supposed that in 60 hours (time of implant 
contact with CAM), around 9% of CA (12.5 µg) must 
be liberated. Hence, we expected that CA-loaded PLGA 
implants have led the same effect of CA 250 µg mL-1 
suspension. However, this effect was not observed. In 
all likelihood, due to the hydrophobic structure of CA 
and consequently its higher affinity for the matrix, the 
burst event does not occur immediately, which means 
that more than 60 hours are required for this may 
happen. Therefore, even CA-loaded PLGA implants 
have reduced the vascularity, just CA suspension 
presented an antiangiogenic effect comparable with 
bevacizumab. 
FIGURE 7 - CAM assay performed with PBS pH 7.4 (negative control), the blank implant of PLGA; CA-loaded PLGA implant; 
CA suspension at 250 µg ml-1 and bevacizumab 250 µg ml-1 (positive control). The negative control was fixed at 100%. Results 
are expressed as mean (%)±SEM; *p<0.05; **p<0.01; ***p<0.001 compared to the negative control.
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FIGURE 8 - Photographs of CAM treated with (A) PBS (B) blank implant (C) PLGA+AC implant (D) bevacizumab.
CONCLUSION
In this study, CA-loaded PLGA polymeric devices 
were successfully fabricated by the hot melt method and 
the drug showed to be dispersed uniformly in the matrix. 
The systems were physicochemical characterized by 
FTIR and DSC and no chemical interaction between the 
components of the formulation was verified. The in vitro 
release profile demonstrated that the PLGA-CA 
implants allowed a prolonged and controlled release 
of the triterpene, which was confirmed by SEM. In 
addition, the developed devices showed no toxicity and 
presented an antiangiogenic effect. Finally, this work 
provided a novel and interesting delivery system for CA, 
which presents as a promising therapeutic tool for the 
treatment of angiogenic pathologies.
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